Mintrax S 1000mg/500mg Injection
Marketer
Mint Life Sciences Pvt Ltd
Salt Composition
Ceftriaxone (1000mg) + Sulbactam (500mg)
Overview Mintrax S 1000mg/500mg Injection
Combiflox 1000mg/500mg Injection is a dual-action antibiotic indicated for diverse bacterial infections. Its mechanism combats microbial proliferation, thus hindering infection spread. Administration of Combiflox 1000mg/500mg Injection necessitates strict adherence to a healthcare provider's guidance. Consistent medication adherence is crucial, completing the prescribed course regardless of symptom improvement. Premature cessation may compromise treatment efficacy. Potential side effects, including nausea, vomiting, diarrhea, and dyspepsia, may occur. Worsening side effects warrant immediate medical attention. Seek emergency care for allergic responses (e.g., skin rashes, pruritus, edema, dyspnea). Prior to commencing treatment, disclose all current medications and pre-existing conditions to your physician. This is especially important for pregnant or lactating individuals. Alcohol consumption should be avoided due to potential additive drowsiness. While typically non-impairing, driving should be avoided if drowsiness or dizziness occurs. Adequate rest, balanced nutrition, and sufficient hydration promote recovery. Your doctor may order tests to monitor treatment response.
Uses of Mintrax S 1000mg/500mg Injection
Infections caused by bacteria
Major Benefits of Mintrax S 1000mg/500mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Mintrax S 1000mg/500mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Mintrax S 1000mg/500mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
How Mintrax S 1000mg/500mg Injection works:
Mintrax S Injection, containing 1000mg Ceftriaxone and 500mg Sulbactam, combines an antibiotic with a beta-lactamase inhibitor. Ceftriaxone's antibacterial action disrupts bacterial cell wall synthesis, crucial for bacterial viability. Sulbactam counteracts bacterial resistance mechanisms, thereby boosting Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions associated with the concurrent use of alcohol and Mintrax S 1000mg/500mg Injection.
PregnancySAFE IF PRESCRIBED
The injectable medication Mintrax S (1000mg/500mg) is typically deemed safe for use during gestation. Preclinical trials in animals have revealed minimal or absent harm to the fetus; nonetheless, clinical data from human subjects are scarce.
Breast feedingCAUTION
Administering Mintrax S 1000mg/500mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingUNSAFE
Administration of Mintrax S 1000mg/500mg Injection can induce drowsiness, visual disturbances, and dizziness. Refrain from operating vehicles should these effects manifest.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Mintrax S 1000mg/500mg Injection to individuals with renal impairment. Physician consultation is recommended.
LiverCAUTION
Patients with severe hepatic impairment should use Mintrax S 1000mg/500mg Injection cautiously, potentially requiring dosage modification. Consult a physician for guidance. Dosage alteration for Mintrax S 1000mg/500mg Injection is unnecessary in individuals with mild to moderate liver dysfunction.
What if you forget to take Mintrax S 1000mg/500mg Injection :
Omit a dose of Mintrax S 1000mg/500mg Injection? Seek medical advice immediately.
Facts to Know About Mintrax S 1000mg/500mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobials |
3,018 People bought this recently